Prescott Group Capital Management L.L.C. raised its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 33.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 361,750 shares of the company's stock after buying an additional 90,000 shares during the quarter. Prescott Group Capital Management L.L.C. owned about 0.63% of Ginkgo Bioworks worth $3,552,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of DNA. Charles Schwab Investment Management Inc. grew its stake in shares of Ginkgo Bioworks by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company's stock worth $2,295,000 after purchasing an additional 17,372 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Ginkgo Bioworks during the 4th quarter worth $29,000. SVB Wealth LLC acquired a new position in shares of Ginkgo Bioworks during the 4th quarter worth $171,000. Bank of New York Mellon Corp grew its stake in shares of Ginkgo Bioworks by 48.2% during the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock worth $226,000 after purchasing an additional 7,503 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Ginkgo Bioworks during the 4th quarter worth $154,000. 78.63% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Trading Down 3.2 %
Shares of NYSE:DNA traded down $0.25 on Friday, reaching $7.56. 1,403,670 shares of the company were exchanged, compared to its average volume of 1,392,189. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $50.40. The firm has a market cap of $434.71 million, a price-to-earnings ratio of -0.58 and a beta of 1.23. The company has a 50-day moving average of $11.32 and a 200-day moving average of $9.30.
About Ginkgo Bioworks
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
